HBOC

GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare

Retrieved on: 
Monday, March 25, 2024
Ovarian cancer, Health, Comprehensive, Cardiovascular disease, Gene, Genetic testing, DSM-IV codes, Risk, Patient, HBOC, Breast, Risk assessment, Publication, Cancer, Breast cancer, Physician, Vaccine

Oncology, Cardiovascular, and Metabolic Disease Coverage: GeneType's Comprehensive Risk Assessment Test covers a diverse range of diseases, providing physicians and patients with a complete understanding of an individual's risk profile.

Key Points: 
  • Oncology, Cardiovascular, and Metabolic Disease Coverage: GeneType's Comprehensive Risk Assessment Test covers a diverse range of diseases, providing physicians and patients with a complete understanding of an individual's risk profile.
  • With an increasing emphasis on personalized medicine and preventative healthcare, the demand for comprehensive genetic risk assessments is expected to grow significantly.
  • GENE’s CEO Simon Morriss, commented “As pioneers in risk assessment testing, we are thrilled to introduce our latest GeneType Comprehensive Risk Assessment Test.
  • The Comprehensive Risk Assessment Test marks a significant step towards realizing this vision, offering a transformative tool for healthcare providers and their patients.

Bionano Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance

Retrieved on: 
Tuesday, March 19, 2024
Ovarian cancer, DNA repair, Breast, SAN, Neoplasm, DNA, HBOC, Doctor of Philosophy, Medicine, Genomics, Chromothripsis, SVS, Breast cancer, HRD, BRCA2, OGM, BRCA1, Drug resistance, Medical imaging

HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.

Key Points: 
  • HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.
  • The study authors selected OGM for this analysis due to its ability to detect multiple classes of SVs with genome-wide coverage, high resolution and accuracy.
  • Eight novel gene fusions were identified by OGM, including three that had not previously been detected by other methods of analysis.
  • “We are pleased to see the publication of this study, which highlights OGM as a promising tool for detecting novel variants in HBOC-related breast cancer that have oncogenic potential.

LetsGetChecked Launches myGeneticScreen, a Genetic Testing Service Designed to Deliver Personalized, Actionable Insights into Predisposition for Inherited Cancers and Cardiovascular Diseases

Retrieved on: 
Wednesday, February 21, 2024
Medical Devices, Genetics, Health Technology, Telemedicine, Virtual Medicine, Cardiology, Biotechnology, Health, General Health, Oncology, Genetic counseling, Cardiovascular disease, FACMG, Hereditary nonpolyposis colorectal cancer, Ovarian cancer, Risk, Disease, Patient, Genetic testing, HBOC, Gene, Knowledge, Genomics, CDC, FH, Mortality, Familial hypercholesterolemia, Cancer

LetsGetChecked, a global healthcare solutions company, announced today the launch of myGeneticScreen, a genetic testing service designed to provide patients with valuable and actionable insights into their predisposition for certain hereditary conditions with end-to-end support, including personalized health reports and access to genetic counseling.

Key Points: 
  • LetsGetChecked, a global healthcare solutions company, announced today the launch of myGeneticScreen, a genetic testing service designed to provide patients with valuable and actionable insights into their predisposition for certain hereditary conditions with end-to-end support, including personalized health reports and access to genetic counseling.
  • This addition to LetGetChecked’s genetics portfolio strengthens the company’s commitment to empowering people with accessible health information and care to live longer, happier lives.
  • Using a saliva specimen, myGeneticScreen analyzes 11 genes associated with three conditions recommended by the Centers for Disease Control and Prevention (CDC) as actionable Tier 1 conditions.
  • Offering a best-in-class experience, the genetic testing service includes pre- and post- genetic counseling.

Launching our most comprehensive test and expanding into new global markets

Retrieved on: 
Wednesday, January 31, 2024
Partnership, Medical director, Policy, Growth, Memorandum of understanding, Workflow, Hospital, Research, GTG, Clinical trial, Risk assessment, Alternative medicine, General practice, Patient, Government, Personalized medicine, Medicine, Health, Gold Coast Private Hospital, Genomics, HBOC, NPA, Affinity, MRFF, Family medicine, Medical Research Future Fund, Business, DSM-IV codes, Pharmaceutical industry

Record number of geneType tests processed, with six times more commercial samples received compared to the prior corresponding period.

Key Points: 
  • Record number of geneType tests processed, with six times more commercial samples received compared to the prior corresponding period.
  • Launched Hereditary Breast & Ovarian Cancer Risk Assessment Test (HBOC) via an exclusive Santa Monica event for a select group of clinicians.
  • Discussions continue with potential partners to access Indonesia's healthcare market, with the geneType Multi-Risk test
    Expanding Global Footprint UK.
  • GTG believes results from this trial will form an important step in introducing risk assessments test such as geneType into routine general practice.

Jay Roche has joined iVitaFi as vice president of healthcare sales

Retrieved on: 
Monday, April 10, 2023
Growth, Allscripts, Hospital, Patient, Health, HBOC, Patient satisfaction, McKesson Corporation, Health insurance

ATLANTA, April 10, 2023 /PRNewswire/ -- iVitaFi announced Jay Roche has joined the company as vice president of healthcare sales.

Key Points: 
  • ATLANTA, April 10, 2023 /PRNewswire/ -- iVitaFi announced Jay Roche has joined the company as vice president of healthcare sales.
  • As VP of healthcare sales, Jay will lead all sales efforts that drive growth for the company.
  • He has over forty-years of experience in healthcare product, management, decision support and all aspects of healthcare sales.
  • Before joining iVitaFi, Jay spent 8 years as a sales leader in the Northeast for CommerceHealthcare and in the Midwest/Atlantic states for ClearBalance HealthCare.

GENE to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer

Retrieved on: 
Friday, February 3, 2023
Health, Breast cancer, Family, ASX, Consumer, Genetypes, Classification, Cancer, BRCA, Hereditary breast–ovarian cancer syndrome, Risk, Survival, Heredity, Ovarian cancer, HBOC, Risk assessment, GTG, Woman, Business-to-business, Birth control, Breast

Combined with other clinical risk factors the test provides a comprehensive risk assessment in a simple saliva test.

Key Points: 
  • Combined with other clinical risk factors the test provides a comprehensive risk assessment in a simple saliva test.
  • New test integrates the patented and proprietary GeneType platform for both Breast and Ovarian Cancer.
  • GTG’s unique approach “appends” the detection of the 13 major “actionable” breast and ovarian cancer susceptibility genes to the GeneType test platform.
  • Our non-invasive risk assessment test will address cancer risk at a population health level.”
    Authorised for release by the board of directors of Genetic Technologies Limited.

VirTech Bio presenting at the Florida Venture Summit Dec. 6, 2022

Retrieved on: 
Thursday, December 1, 2022
Multiplicity (chemistry), Science, Blood, HBOC, IND, MM, Hypovolemia, CGMP, Death, MD, Bleeding, Patent, Medicine, United States Department of Defense, Medical device, Pharmaceutical industry

Dr. Hack became CEO of VirTech Bio in March 2022.

Key Points: 
  • Dr. Hack became CEO of VirTech Bio in March 2022.
  • VirTech Bio has previously raised seed funding of $6.7 MM which leverages $13.7 MM awarded in non-dilutive funding to date, primarily from the DoD.
  • The Florida Venture Summit is being held in Miami (Dec. 6 -7, 2022) and is billed as a premier event 'Where Innovation Meets Capital'.
  • For more information about VirTech Bio contact us at: [email protected] .